Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

Background: Acute promyelocytic leukaemia is a chemotherapy-sensitive subgroup of acute myeloid leukaemia characterised by the presence of the PML-RARA fusion transcript. The present standard of care, chemotherapy and all-trans retinoic acid (ATRA), results in a high proportion of patients being cur...

Descripción completa

Detalles Bibliográficos

Publicado en:	Lancet Oncology Vol. 16; no. 13; pp. 1295 - 1306
Autores principales:	Burnett, Alan K, Russell, Nigel H, Hills, Robert K, Bowen, David, Kell, Jonathan, Knapper, Steve, Morgan, Yvonne G, Lok, Jennie, Grech, Angela, Jones, Gail, Khwaja, Asim, Friis, Lone, McMullin, Mary Frances, Hunter, Ann, Clark, Richard E, Grimwade, David
Formato:	research randomized controlled trial Journal Article
Publicado:	Elsevier B.V. Oct2015
Acceso en línea:	Ver este registro en EBSCOhost